Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

How BlackThorn rebounded from a January clinical setback to raise $76 million to develop its targeted therapies for neurobehavioral disorders

Inhua Muijrers-Chen, Associate Editor
June 13, 2019 12:31 PM UTC

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders.

New investors Polaris Partners, Premier Partners, Scripps Research and Vertex Ventures HC participated in the round alongside existing investors Alexandria Venture Investments, Altitude Life Science Ventures, Arch Venture Partners, Biomatics Capital, GV, Johnson & Johnson Innovation -- JJDC Inc. and Mercury Fund. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

BlackThorn Therapeutics Inc.